AZD9291 in EGFR -Mutant Advanced Non-Small-Cell Lung Cancer Patients

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · see citing works

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246 · see citing works

Liquid Biopsies: Genotyping Circulating Tumor DNA

Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210 · see citing works

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · see citing works

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116 · see citing works

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · see citing works

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624 · see citing works

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598 · see citing works

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589 · see citing works

Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma

Schouten, L. J., Rutten, J., Huveneers, H. A. M., & Twijnstra, A. (2002) · Cancer · doi:10.1002/cncr.10541 · Cited by 1,584 · see citing works

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574 · see citing works

Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna

(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,174 · see citing works

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic <i>EGFR</i> Mutations

Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820 · see citing works

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684 · see citing works

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665 · see citing works

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636 · see citing works

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J., Chmielecki, J., Kris, M. G., Pao, W., Ladanyi, M., & Miller, V. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2692 · Cited by 627 · see citing works

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583 · see citing works

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574 · see citing works

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 539 · see citing works

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K. E., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M. E., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 519 · see citing works

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 458 · see citing works

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00121-7 · Cited by 413 · see citing works

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Watanabe, S., Tanaka, J., Ota, T., Kondo, R., Tanaka, H., Kagamu, H., Ichikawa, K., Koshio, J., Baba, J., Miyabayashi, T., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-1 · Cited by 392 · see citing works

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer

Regales, L., Gong, Y., Shen, R., de Stanchina, E., Vivanco, I., Goel, A. J., Koutcher, J. A., Spassova, M. K., Ouerfelli, O., Mellinghoff, I. K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38746 · Cited by 371 · see citing works

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Ercan, D., Choi, H. G., Yun, C.-H., Capelletti, M., Xie, T., Eck, M. J., Gray, N. S., & Jänne, P. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2789 · Cited by 368 · see citing works

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant <i>EGFR</i> -Mutant Lung Cancer with and without T790M Mutations

Janjigian, Y. Y., Smit, E. F., Groen, H. J. M., Horn, L., Gettinger, S., Camidge, D. R., Riely, G. J., Wang, B., Fu, Y., Chand, V. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0326 · Cited by 362 · see citing works

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Yu, H. A., Sima, C. S., Huang, J. G., Solomon, S. B., Rimner, A., Paik, P. K., Pietanza, M. C., Azzoli, C. G., Rizvi, N. A., Krug, L. M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827e1f83 · Cited by 340 · see citing works

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

Planchard, D., Loriot, Y., André, F., Gobert, A., Auger, N., Lacroix, L., & Soria, J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv319 · Cited by 312 · see citing works

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Eberlein, C. A., Stetson, D., Markovets, A. A., Al-Kadhimi, K. J., Lai, Z., Fisher, P. R., Meador, C. B., Spitzler, P. J., Ichihara, E., Ross, S. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3167 · Cited by 304 · see citing works

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Rosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2158 · Cited by 304 · see citing works

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

Doebele, R. C., Lu, X. J. D., Sumey, C. J., Maxson, D. A., Weickhardt, A. J., Oton, A. B., Bunn, P. A., Barón, A. E., Franklin, W. A., Aisner, D. L., et al. (2012) · Cancer · doi:10.1002/cncr.27409 · Cited by 279 · see citing works

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Hoffknecht, P., Tufman, A., Wehler, T., Pelzer, T., Wiewrodt, R. G., Schütz, M., Serke, M. H., Stöhlmacher-Williams, J., Märten, A., Huber, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000380 · Cited by 255 · see citing works

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Eskens, F. A. L. M., Mom, C. H., Planting, A. S. T., Gietema, J. A., Amelsberg, A., Huisman, H., van Doorn, L., Burger, H., Stopfer, P., Verweij, J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604108 · Cited by 234 · see citing works

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

Kuang, Y., Rogers, A. M., Yeap, B. Y., Wang, L., Makrigiorgos, M. G., Vetrand, K., Thiede, S., Distel, R. J., & Janne, P. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2592 · Cited by 230 · see citing works

Clinical Predictors of Metastatic Disease to the Brain from Non–Small Cell Lung Carcinoma: Primary Tumor Size, Cell Type, and Lymph Node Metastases

Mujoomdar, A., Austin, J. H. M., Malhotra, R., Powell, C. A., Pearson, G. D. N., Shiau, M. C., & Raftopoulos, H. (2007) · Radiology · doi:10.1148/radiol.2423051707 · Cited by 229 · see citing works

The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229 · see citing works

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

Omuro, A. M. P., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N. T., Milton, D. T., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21033 · Cited by 227 · see citing works

Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR

Watanabe, M., Kawaguchi, T., Isa, S.-I., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2151 · Cited by 216 · see citing works

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer

Tricker, E. M., Xu, C., Uddin, S., Capelletti, M., Ercan, D., Ogino, A., Pratilas, C. A., Rosen, N. X., Gray, N. S., Wong, K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0063 · Cited by 207 · see citing works

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., & Riely, G. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt573 · Cited by 206 · see citing works

Frequent EGFR mutations in brain metastases of lung adenocarcinoma

Matsumoto, S., Takahashi, K., Iwakawa, R., Matsuno, Y., Nakanishi, Y., Kohno, T., Shimizu, E., & Yokota, J. (2006) · International Journal of Cancer · doi:10.1002/ijc.21940 · Cited by 181 · see citing works

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations

Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Fujita, S., Kaji, R., Imai, Y., Monden, K., et al. (2013) · Cancer · doi:10.1002/cncr.28364 · Cited by 178 · see citing works

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice

Gahr, S., Stoehr, R., Geissinger, E., Ficker, J. H., Brueckl, W. M., Gschwendtner, A., Gattenloehner, S., Fuchs, F. S., Schulz, C. K. J., Rieker, R. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.511 · Cited by 149 · see citing works

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Metastatic to the Brain

Jamal‐Hanjani, M., & Spicer, J. F. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2529 · Cited by 146 · see citing works

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

Ramalingam, S. S., Janne, P. A., Mok, T. S. K., O'Byrne, K. J., Boyer, M. J., von Pawel, J., Płużański, A., Shtivelband, M. I., Docampo, L. I., Bennouna, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70452-8 · Cited by 140 · see citing works

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors

Sun, J., Ahn, M., Choi, Y., Ahn, J. S., & Park, K. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.023 · Cited by 118 · see citing works

EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases?

Hendriks, L. E. L., Smit, E. F., Vosse, B. A. H., Mellema, W. W., Heideman, D. A. M., Bootsma, G. P., Westenend, M., Pitz, C. C. M., de Vries, G. J., Houben, R. M. A., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.01.006 · Cited by 117 · see citing works

Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall‐cell lung cancer

Lee, Y. J., Choi, H. J., Kim, S. I., Chang, J., Moon, J. W., Park, I. K., Kim, J.-H., & Cho, B. C. (2010) · Cancer · doi:10.1002/cncr.24877 · Cited by 106 · see citing works

Common <i>EGFR</i> -Mutated Subgroups (Del19/L858R) in Advanced Non-Small-Cell Lung Cancer: Chasing Better Outcomes with Tyrosine Kinase Inhibitors

Reguart, N., & Remon, J. (2015) · Future Oncology · doi:10.2217/fon.15.15 · Cited by 91 · see citing works

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA

Nakamura, T., Sueoka‐Aragane, N., Iwanaga, K., Sato, A., Komiya, K., Abe, T., Ureshino, N., Hayashi, S., Hosomi, T., Hirai, M., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822956e8 · Cited by 74 · see citing works

Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).

Kim, D., Lee, K. H., Kang, J. H., Park, K., Han, J., Lee, J.-S., Jang, I., Kim, H.-Y., Son, J., & Kim, J.-H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8011 · Cited by 70 · see citing works

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection

Hata, A., Katakami, N., Yoshioka, H., Fujita, S., Kunimasa, K., Nanjo, S., Otsuka, K., Kaji, R., Tomii, K., Iwasaku, M., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.03.010 · Cited by 65 · see citing works

Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC

Bosc, C., Ferretti, G., Cadranel, J. L., Audigier-Valette, C., Besse, B., Barlési, F., Decroisette, C., Lantuéjoul, S., Arbib, F., & Moro‐Sibilot, D. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0332-y · Cited by 61 · see citing works

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer

Kaira, K., Naito, T., Takahashi, T., Ayabe, E., Shimoyama, R., Kaira, R., Ono, A., Igawa, S., Shukuya, T., Murakami, H., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.006 · Cited by 61 · see citing works

Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).

Sequist, L. V. D., Goldman, J. W., Wakelee, H. A., Camidge, D. R., Yu, H. A., Varga, A., Solomon, B., Oxnard, G. R., Ou, S. I., Papadimitrakopoulou, V. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8001 · Cited by 54 · see citing works

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer

Oxnard, G. R., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Yu, H. A., Saka, H., Horn, L., Goto, K., Ohe, Y., Cantarini, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2509 · Cited by 46 · see citing works

The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis

Lü, S., Ding, D., Yu, Y., Li, Z., & Niu, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s58870 · Cited by 40 · see citing works

Aspiration: First-Line Erlotinib (E) Until and Beyond Recist Progression (Pd) in Asian Patients (Pts) with Egfr Mutation-Positive (Mut+) Nsclc

Park, K., Ahn, M., Yu, C., Kim, S., Lin, M., Sriuranpong, V., Tsai, C.-M., Lee, J., Kang, J. H., Perez-Moreno, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu349.2 · Cited by 39 · see citing works

Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer

Meador, C. B., Jin, H., de Stanchina, E., Nebhan, C. A., Pirazzoli, V., Wang, L., Wang, L., Vuong, H., Hutchinson, K. E., Jia, P., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0723 · Cited by 31 · see citing works

Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer

Lee, Y., Lee, G. K., Hwang, J.-A., Yun, T., Kim, H. T., & Lee, J. S. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.09.002 · Cited by 28 · see citing works

Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases.

Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Masago, K., Fujita, S., Kaji, R., Imai, Y., Monden, K., et al. (2015) · PubMed · Cited by 26 · see citing works

Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)

Kim, D. S., Yang, J. C., Cross, D. A. E., Ballard, P. G., Yang, P., Yates, J. W. T., Xie, L., Cantarini, M., Ghiorghiu, S., & Janne, P. A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu331.16 · Cited by 21 · see citing works

A Phase I Study of AZD9291 in Patients with Egfr-Tki-Resistant Advanced Nsclc – Updated Progression Free Survival and Duration of Response Data

Janne, P. A., Ahn, M., Kim, D.-W., Kim, S., Planchard, D., Ramalingam, S. S., Frewer, P., Cantarini, M., Ghiorghiu, S., & Yang, J. C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv128.05 · Cited by 18 · see citing works

Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer

Re, M. D., Vasile, E., Falcone, A., Danesi, R., & Petrini, I. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.908120 · Cited by 18 · see citing works

Levels of Egfr T790M in Plasma Dna As a Predictive Biomarker for Response to Azd9291, a Mutant-Selective Egfr Kinase Inhibitor

Thress, K. S., Yang, J. C.-H., Ahn, M.-J., Kim, D. S., Kim, S., Ohe, Y., Planchard, D., Brant, R., Carr, T. H., Dearden, S. P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu349.49 · Cited by 7 · see citing works

Preliminary Azd9291 Western and Asian Clinical Pharmacokinetics (Pk) in Patients (Pts) and Healthy Volunteers (Hv): Implications for Formulation, Dose and Dosing Frequency in Pivotal Clinical Studies

Planchard, D., Dickinson, P. A., Brown, K. H., Kim, D. S., Kim, S., Ohe, Y., Felip, E., Leese, P. T., Cantarini, M., & Ranson, M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu331.24 · Cited by 3 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance

Wang, S., Song, Y., & Liu, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.008 · Cited by 302 · see citing works

Autophagy and pulmonary disease

Liao, S., Sun, P., Gu, Y., Rao, X., Zhang, L., & Ouyang, Y. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619890538 · Cited by 94 · see citing works

Consensus on precision medicine for metastatic cancers: a report from the MAP conference

Swanton, C., Soria, J., Bardelli, A., Biankin, A. V., Caldas, C., Chandarlapaty, S., de Koning, L., Dive, C., Feunteun, J., Leung, S.-Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw192 · Cited by 92 · see citing works

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence

Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104 · see citing works

Targeted therapies for advanced non-small cell lung cancer

Ai, X., Guo, X., Wang, J., Stancu, A. L., Joslin, P. M. N., Zhang, D., & Zhu, S. (2018) · Oncotarget · doi:10.18632/oncotarget.26428 · Cited by 59 · see citing works

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group

written on behalf of the AME Lung Cancer Collaborative Group, Jiang, T., Su, C., Ren, S., Cappuzzo, F., Rocco, G., Palmer, J. D., van Zandwijk, N., Blackhall, F. H., Le, X., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.61 · Cited by 53 · see citing works

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study

Schmid, S., Klingbiel, D., Aeppli, S., Britschgi, C., Gautschi, O. P., Pless, M., Rothschild, S. I., Wannesson, L., Janthur, W.-D., Förbs, D., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.020 · Cited by 54 · see citing works

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

Ricciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 39 · see citing works

Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models

Corte, C. M. D., Ciaramella, V., Cardone, C., Monica, S. L., Alfieri, R. R., Petronini, P. G., Malapelle, U., Vigliar, E., Pepe, F., Troncone, G., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.025 · Cited by 36 · see citing works

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

Depo-Provera, P. (2015) · Cited by 35 · see citing works

Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S

Assadollahi, V., Rashidieh, B., Alasvand, M., Abdolahi, A., & López, J. A. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28575 · Cited by 29 · see citing works

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics

Liao, Y.-Y., Tsai, C.-L., & Huang, H. (2025) · Cancers · doi:10.3390/cancers17030459 · Cited by 28 · see citing works

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers

Choi, B., Cha, M., Eun, G. S., Lee, D. H., Lee, S., Ehsan, M., Chae, P. S., Heo, W. D., Park, Y., & Yoon, T. (2020) · eLife · doi:10.7554/elife.53934 · Cited by 27 · see citing works

Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels

Li, P., Tian, X., Wang, G., Jiang, E., Li, Y., & Hao, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1177003 · Cited by 24 · see citing works

Autophagy-related signaling pathways in non-small cell lung cancer

Wang, J., Gong, M., Fan, X., Huang, D., Zhang, J., & Huang, C. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04280-5 · Cited by 22 · see citing works

Standing on the shoulders of giants: a retrospective analysis of kinase drug discovery at AstraZeneca

Kettle, J. G., & Wilson, D. M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.007 · Cited by 22 · see citing works

Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond

Li, X., Lin, Y., Song, L., Huang, J., & Ruan, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1404692 · Cited by 18 · see citing works

Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib

Ren, X., Cai, X., Li, J., Zhang, X., Yu, J., Song, X., Zhang, H., & Song, X. (2020) · Journal of International Medical Research · doi:10.1177/0300060520927918 · Cited by 18 · see citing works

Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy

Rydén, A., Blackhall, F. H., Kim, H. R., Pillai, R. N., Braam, L., Martin, M. L., & Walding, A. (2017) · Patient · doi:10.1007/s40271-017-0229-9 · Cited by 13 · see citing works

The roles, controversies, and combination therapies of autophagy in lung cancer

Wang, Z., Zhou, C., & Yang, S. (2021) · Cell Biology International · doi:10.1002/cbin.11704 · Cited by 13 · see citing works

13-Oxyingenol-dodecanoate inhibits the growth of non-small cell lung cancer cells by targeting ULK1

Wang, X., Wang, Y.-J., Guo, B., Hou, Z., Zhang, G.-X., Han, Z., Liu, Q., Yao, G., & Song, S. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107367 · Cited by 9 · see citing works

Discovery of a Novel EGFR PROTAC Degrader against C797S Resistance Mutation with Potent Antitumor Efficacy in NSCLC Treatment

Wang, X., Wang, C., Ma, Y., Piao, Y., Shi, Y., Yang, S., Li, J., & Fan, Y. L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00693 · Cited by 8 · see citing works

Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report

Wang, J., Wang, H., Kong, L., Yu, J., & Zhu, H. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1491504 · Cited by 6 · see citing works

Consensus on precision medicine for metastatic cancers: A report from the MAP

Swanton, C., Bardelli, A., Biankin, A. V., Caldas, C., Chandarlapaty, S., André, F., Roussy, G., Xi, P.-S., & Wohl, W. (2016) · Cited by 3 · see citing works

Prise en charge des métastases cérébrales des cancers du poumon

Monnet, I., Rousseau-Bussac, G., Jabot, L., & CHOUAID, C. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2636-2 · Cited by 1 · see citing works

Modern Approaches to Anti-EGFR Therapy

Владимировна, Д. Е., Nadyrova, A. I., Luginskaya, S., Kosnyrev, A. S., Владимировна, У. В., & Ilinskaya, O. N. (2025) · Molecular Biology · doi:10.1134/s0026893325700347 · Cited by 1 · see citing works

Cytoskeletal remodeling via CAMSAP3 downregulation drives resistance to osimertinib in NSCLC cells

Yang, F., Wang, Z., Han, X., Zhong, J., Hou, Z., Bian, S., Long, J., & Liu, H. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08299-0 · Cited by 1 · see citing works

Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cells

Park, S. S., Lee, H. W., Kwon, M. R., Ju, E. J., Shin, S. H., Park, J., Ko, E. J., Son, G. W., Kim, Y. J., Moon, G. J., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03475-1 · Cited by 1 · see citing works

Métastases cérébrales des cancers bronchiques non à petites cellules (CBNPC)

Monnet, I. (2017) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(17)30059-9

Advancements in oncotherapeutics drive positive outcomes in cancer

Ladd, J. (2017) · Pharmacy Today · doi:10.1016/j.ptdy.2017.06.019

Targeted Agents and Immunotherapy

Ranjan, T., Podder, V., & Ahluwalia, M. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-67743-4_31

In Silico Screening and Structural Optimization of Curcumin Derivatives with Potential Anticancer ActivityPreprint

Ghotane, R. B., Charde, M. S., Chakole, R. D., Bhandari, S. V., & Shimpi, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-7082373/v1

AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials.

Bazo, I. G., & Rolfo, C. D. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.07.02 · Cited by 8 · see citing works

AZD9291 in epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.

Stinchcombe, T. E. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.07.19 · Cited by 9 · see citing works

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.

Jiang, T., & Zhou, C. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.08.02 · Cited by 77 · see citing works

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246 · see citing works

Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.

Cross, D. A. E., Ashton, S., Nebhan, C. A., Eberlein, C., Finlay, M. R. V., Hughes, G., Jacobs, V. N., Mellor, M. J., Brewer, M. R., Meador, C. B., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-a109 · Cited by 19 · see citing works